Lyell Immunopharma (LYEL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Lyell Immunopharma (LYEL) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.23 of bullish evidence against -0.41 bearish.

Lyell Immunopharma last closed at $8.56, -0.58% on the session.

Against the IVW growth benchmark the position is -0.42% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

18 graded predictions for LYEL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Lyell Immunopharma in the 12th percentile on return on equity, where 100 is best.

Lyell Immunopharma is classified under Health Care / Biotechnology, with a market capitalisation of $210.99M.

StockMap tracks Lyell Immunopharma as the 241st largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Lyell Immunopharma ranks 319th of 377 in the group, against a group median of -0.21.